Sistema de Salut de Catalunya
Institut Català de la Salut
[Serrano C] Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Martín-Broto J] Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid, Spain University Hospital General de Villalba, Madrid, Spain Instituto de investigación Sanitaria Fundación Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain. [Asencio-Pascual JM] Department of General Surgery, Gregorio Marañón University Hospital, Madrid, Spain Department of Surgery, Universidad Complutense de Madrid, Madrid, Spain. [López-Guerrero JA] Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain. [Rubió-Casadevall J] Department of Medical Oncology, Catalan Institute of Oncology, Girona Biomedical Research Institute (IDIBGI), Girona, Spain. [Bagué S] Department of Pathology, Santa Creu i Sant Pau University Hospital, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-09-19T08:54:00Z
2023-09-19T08:54:00Z
2023
Avapritinib; Gastrointestinal stromal tumor; Surgery
Avapritinib; Tumor estromal gastrointestinal; Cirurgia
Avapritinib; Tumor estromal gastrointestinal; Cirugía
Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with essentially no metastatic potential to malignant and life-threatening spread diseases. Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinases are the crucial drivers of most GISTs, responsible for tumor initiation and evolution throughout the entire course of the disease. The introduction of tyrosine kinase inhibitors targeting these receptors has substantially improved the outcomes in this formerly chemoresistant cancer. As of today, five agents hold regulatory approval for the treatment of GIST: imatinib, sunitinib, regorafenib, ripretinib, and avapritinib. This, in turn, represents a success for a rare neoplasm. During the past two decades, GIST has become a paradigmatic model in cancer for multidisciplinary work, given the disease-specific particularities regarding tumor biology and tumor evolution. Herein, we review currently available evidence for the management of GIST. This clinical practice guideline has been developed by a multidisciplinary expert panel (oncologist, pathologist, surgeon, molecular biologist, radiologist, and representative of patients’ advocacy groups) from the Spanish Group for Sarcoma Research, and it is conceived to provide, from a critical perspective, the standard approach for diagnosis, treatment, and follow-up.
This work was supported in part by AECC (CLSEN20004SERR) and the Fero Foundation, both to CS.
Article
Published version
English
Tracte gastrointestinal - Càncer - Tractament; Tracte gastrointestinal - Càncer - Diagnòstic; DISEASES::Digestive System Diseases::Digestive System Neoplasms::Gastrointestinal Neoplasms::Digestive System Diseases::Gastrointestinal Stromal Tumors; Other subheadings::Other subheadings::Other subheadings::/drug therapy; HEALTH CARE::Health Services Administration::Patient Care Management::Disease Management; ENFERMEDADES::enfermedades del sistema digestivo::neoplasias del sistema digestivo::neoplasias gastrointestinales::enfermedades del sistema digestivo::tumores del estroma gastrointestinal; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::tratamiento de las enfermedades
SAGE Publications
Therapeutic Advances in Medical Oncology;15
https://doi.org/10.1177/17588359231192388
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
